Lumateperone has been ranked favorably among adjunctive therapies for major depressive disorder. It is reported to have ranked highest in a network meta-analysis, although the specifics of the ranking and analysis are not detailed. The ranking is part of a broader review of updates on the psychiatric treatment pipeline.